Biobeat key facts
as of Oct 2026- Developer of a wearable remote patient monitoring device designed to measure vital signs using wireless, non-invasive, and medical-grade technology.
- Biobeat is valued at approximately $102.7M as of Oct 2026 (last reported valuation).
- It has raised $71.8M; the latest was Later Stage VC ($50.0M) in Dec 2025.
- Notable investors include OrbiMed, Ally Bridge Group, and Ventures, Elevage Medical Technologies, ARC Innovation Center — 15 tracked in total.
- Status: Privately Held (backing).
Biobeat's last reported valuation, May 2024. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Biobeat: the Monday email on marks, rounds and moves
Biobeat funding rounds
No funding rounds for Biobeat are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Biobeat
15+Biobeat valuation
Biobeat's last reported valuation was $103 million in May 2024. No priced round, secondary trade or fund mark has surfaced since.
Biobeat investors
15 investors are on record for Biobeat, including OrbiMed, Ally Bridge Group, and Ventures and Elevage Medical Technologies.
About Biobeat
Developer of a wearable remote patient monitoring device designed to measure vital signs using wireless, non-invasive, and medical-grade technology. The company's device specialises in monitoring vital signs and other medically relevant parameters, including consciousness, saturation, pulse, temperature, and perspiration, enabling patients to have control over their everyday life, health, and sickness.
- Sector
- Healthcare
- HQ
- Petah Tikva, Israel
- Founded
- 2014
- Employees
- 71
- Website
- bio-beat.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.